Alvogen agrees biosimilar commercial deals in three major markets

By Staff Reporter

- Last updated on GMT

(Image: Getty/Metamorworks)
(Image: Getty/Metamorworks)

Related tags Alvogen Alvotech Forteo Eli lilly Pfenex

Biosimilar developer agrees three different distribution partners in South Korea, Israel and Canada for biosimilar to Forteo.

Alvogen has signed agreements with PharmBio, Kamada and Jamp, for each country, respectively. The company’s biosimilar, PF708, is still subject to approval in the three countries.

The biosimilar was originally developed by Pfenex, but the two companies entered into a development and commercialization agreement​ that would see Alvogen take the lead in certain European countries, the Middle East, North Africa and the ‘rest of world’ territories.

Earlier this month​, PF708 was approved in the US and is known by the brand name, Bonsity. The biosimilar is also currently going through the regulatory process with the European Medicines Agency.

Forteo (teriparatide) is Eli Lilly’s treatment for men and postmenopausal women with osteoporosis. The treatment managed global sales of $1.6bn (€1.4bn) in 2018.

In addition to securing partners in the three countries, Alvogen also noted that it had submitted for marketing authorization in Saudi Arabia.

Alvogen will manufacture the biosimilar out of its subsidiary’s $250m Iceland-based manufacturing plant​.

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more